Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It treats conditions related to excess gastric acid production in adult patients, such as gastro‑oesophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and stress‑related gastric ulcer prevention. It is indicated for acute management of acid‑related disorders in hospital settings.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide across Europe, Asia, Africa and the Americas.

Pantoprazole is a proton pump inhibitor used to manage disorders associated with excessive gastric acid secretion.

- Gastroesophageal reflux disease (GERD): reduces acid exposure, alleviating heartburn and promoting esophageal healing. - Erosive esophagitis: facilitates ulcer healing and symptom relief in inflamed esophageal tissue. - Zollinger‑Ellison syndrome: controls hypergastrinemia‑driven acid overproduction in this rare endocrine disorder. - Prevention of stress‑related gastric ulcers: lowers the risk of ulcer formation in critically ill or postoperative patients.

Pantoprazole may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often resolving without treatment. - Diarrhea: loose stools that may be self‑limiting. - Nausea: transient feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Dyspepsia: indigestion symptoms.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis that may require specific antibiotics. - Acute interstitial nephritis: kidney inflammation presenting with reduced function. - Severe allergic reactions (anaphylaxis, angioedema): rapid onset swelling, breathing difficulty, requiring emergency care.

When using intravenous pantoprazole, several precautionary measures should be observed to ensure patient safety.

- Assess renal function: adjust therapy in patients with severe renal impairment. - Monitor magnesium levels: prolonged treatment may lead to hypomagnesemia. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: avoid drugs known to have contraindicated interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole can affect the pharmacokinetics of several medicines; awareness of these interactions helps avoid therapeutic failure or toxicity.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activation, potentially decreasing efficacy. - Atazanavir: decreased absorption leading to subtherapeutic antiviral levels. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: may raise serum concentrations, necessitating dose adjustment. - Diazepam: potential rise in plasma levels, monitor for enhanced sedation.